Stopping GLP-1 treatment: weight regain and health outcomes

GLP-1 drugs have transformed obesity treatment, but their use raises an inevitable question: what happens when you stop? Data from multiple clinical trials point in the same direction: about two thirds of the weight lost is regained within the first year after stopping. In this episode of the Barbell Medicine podcast, doctors Jordan Feigenbaum and Austin Baraki review the latest evidence on treatment discontinuation and answer a practical question: is heavy lifting safe when you have osteopenia?

Rebound after stopping a GLP-1: what the trials show

The SURMOUNT-4 trial evaluated tirzepatide (Zepbound/Mounjaro). After 36 weeks of treatment with an average loss of 20% of body weight, participants were randomized into two groups: one continued on the drug and the other switched to placebo, with identical lifestyle support in both arms. The group that stopped tirzepatide regained 14% of their lost weight within 12 months, roughly two thirds of what they had lost.

The STEP-1 extension with semaglutide (Ozempic) showed similar results: average weight loss during treatment was 17%, but net sustained loss fell to 5.5% by week 120. A recent systematic review of 37 trials involving nearly 10,000 adults confirmed the pattern: rebound with the newer GLP-1s runs about 0.8 kg per month, though it is important to note that these drugs produce three to four times more weight loss than most lifestyle interventions.

Cardiometabolic markers follow the same trajectory as weight: HbA1c, blood pressure, total cholesterol, and triglycerides all drift back toward pre-treatment values at a rate that tracks closely with weight regain.

Comparison with lifestyle-only interventions

A common argument is that GLP-1s produce a rebound four times faster than lifestyle changes alone. What that argument omits is that weight loss with diet and exercise is also four times smaller, leaving far less to regain in absolute terms.

The Diabetes Prevention Program followed more than 3,000 adults with prediabetes for 10 years: 62% of the intensive lifestyle group lost 5% or more at one year, but more than half had regained that weight by year 10 despite continuing the program. In the Look AHEAD trial, with over 5,000 adults with type 2 diabetes, fewer than half maintained clinically significant weight loss after four years of continuous intervention.

GLP-1s do not have a monopoly on rebound. The biology of the weight-reduced state pushes the body to recover lost weight regardless of the method used. The difference lies in how much weight is lost in absolute terms.

What the studies do not yet reveal

Available data have a limited time horizon. Open questions include whether regain plateaus around 75% of the total loss or continues beyond that, and what the body composition of regained weight actually looks like. The expectation, based on all other weight-loss interventions, is that it is predominantly fat mass, but cessation trials have not measured this directly.

Managing the transition after stopping

Between two and six weeks after the last dose, appetite and food noise tend to return, with intensity that varies by obesity phenotype. People with more severe obesity, a history of bariatric surgery, or lifelong weight struggles face the greatest difficulty.

The best preparation, when it is possible to maintain treatment, is to build solid habits during the therapeutic window: quality sleep, a structured diet, regular exercise, and stress management. Those habits are what determine who holds on to more weight once the drug stops working.

Training with osteopenia: what the evidence says

The Lift More trial is a direct answer to anyone with osteopenia who wonders whether heavy lifting is safe. It included 101 postmenopausal women with a mean age of 65 and T-scores below -1.0, meaning established osteopenia.

The protocol was high intensity: barbell squat, deadlift, overhead press, five sets of five at 85% or more of one-rep max, twice per week in 30-minute sessions. After eight months, lumbar spine bone mineral density had increased by 2.9%, with zero fractures.

The practical conclusion is clear: osteopenia is not a contraindication to lifting weights. Bone adapts to mechanical load, just as muscle does. Waiting for the condition to worsen before training is the strategy with the worst prognosis.

Conclusion

GLP-1s work while you take them, and their benefits reverse after stopping, in much the same way antihypertensives or statins do. The goal is not to plan an exit from the drug, but to use it as a lever to build the habits that can sustain the results. For those with osteopenia, high-intensity strength training is safe, effective, and necessary.